Company intelligence / Profile preview

Rapid Infection Diagnostics

Calgary, Alberta, Canadaridamr.leeds.ac.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has launched the BSIDx system for rapid identification of pathogens and antibiotic susceptibility from positive blood cultures in under five hours. In preclinical evaluations published in Nature Communications, the system was shown to be up to thirty hours faster than conventional methods. Clinical trials are planned for launch in 2025. All technologies are currently Research Use Only.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic platform (metabolomics-based)Mass spectrometry-based diagnostic
Industry: Metabolite Diagnostics

Partnerships

Alberta Precision Laboratories (APL)Alberta Centre for Advanced Diagnostics at University of Calgary

Beyond the preview

Go deeper on Rapid Infection Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapid Infection Diagnostics.

Explore the full profile